PUBLISHER: The Business Research Company | PRODUCT CODE: 1957716
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957716
Psoriatic arthritis treatment refers to the use of therapies or medications aimed at preventing or reducing a chronic inflammatory condition affecting the joints and the sites where tendons and ligaments attach to bones, known as entheses. These treatments focus on managing skin involvement while alleviating joint pain and improving functional ability.
The primary drug classes used in psoriatic arthritis treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and others. Biologics are medications that are derived from or contain components of living organisms. The various routes of administration include oral, parenteral, and topical, and these treatments are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have impacted the psoriatic arthritis treatment market by raising the cost of imported biologics, targeted synthetic dmards, and specialty medications. Segments such as interleukin inhibitors and jak inhibitors are particularly affected, with North America and Europe being most sensitive due to their reliance on imports. This has led to higher treatment costs and potential delays in patient access. On the positive side, tariffs have encouraged domestic manufacturing, local R&D investment, and innovation in cost-effective psoriatic arthritis therapies.
The psoriatic arthritis treatment market research report is one of a series of new reports from The Business Research Company that provides psoriatic arthritis treatment market statistics, including psoriatic arthritis treatment industry global market size, regional shares, competitors with a psoriatic arthritis treatment market share, detailed psoriatic arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the psoriatic arthritis treatment industry. This psoriatic arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The psoriatic arthritis treatment market size has grown strongly in recent years. It will grow from $13.17 billion in 2025 to $14.36 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to limited availability of advanced therapies, reliance on conventional nsaids and dmards, increasing prevalence of psoriatic arthritis, growing patient awareness, expansion of hospital and retail pharmacy infrastructure.
The psoriatic arthritis treatment market size is expected to see strong growth in the next few years. It will grow to $20.62 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to development of interleukin inhibitors and jak inhibitors, increasing adoption of biologics, growth of personalized medicine approaches, rising telemedicine adoption for chronic disease management, increasing government and insurance support for psoriatic arthritis treatment. Major trends in the forecast period include rising adoption of biologics and targeted synthetic dmards, increased awareness of early diagnosis and management of psoriatic arthritis, growth in personalized treatment approaches for joint and skin symptoms, expansion of hospital and specialty pharmacy distribution channels, integration of telemedicine and remote monitoring for psoriatic arthritis patients.
The rise in healthcare spending is expected to support the expansion of the psoriatic arthritis treatment market in the coming years. Healthcare spending, also referred to as healthcare expenditure, represents the financial resources devoted to delivering healthcare services, products, and programs within a country, region, or healthcare system. Increased healthcare spending facilitates the diagnostic process by funding physician visits, laboratory testing, and imaging procedures. Patients with psoriatic arthritis (PsA) typically undergo thorough evaluations to confirm the diagnosis, assess the severity of joint involvement, and identify any related comorbid conditions. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency that oversees the Medicare and Medicaid programs, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, rising healthcare expenditure is contributing to the growth of the psoriatic arthritis treatment market.
Key companies operating in the psoriatic arthritis treatment market are obtaining approvals for new therapies, such as Cosentyx, to strengthen their market presence and improve profitability. Cosentyx is a medication used in the treatment of autoimmune conditions, including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For instance, in October 2023, Novartis, a Switzerland-based pharmaceutical company, announced that the Food and Drug Administration had approved Cosentyx. Cosentyx is a human interleukin-17A antagonist that works by inhibiting the activity of the IL-17A protein, thereby reducing potential side effects such as swelling, pain, and skin irritation. Clinical evidence shows that Cosentyx can begin relieving psoriatic arthritis symptoms within as little as three weeks, addressing joint pain and tenderness, back pain, and skin-related symptoms.
In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical firm, acquired Nimbus Therapeutics for an undisclosed amount. This acquisition is expected to strengthen Takeda Pharmaceutical's position in the psoriatic arthritis treatment market and expand its product portfolio. Nimbus Therapeutics is a US-based biotechnology company that focuses on developing therapies for psoriatic arthritis.
Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.
North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The psoriatic arthritis treatment market includes revenues earned by entities by reducing pain and swelling and controlling inflammation and pain. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Psoriatic Arthritis Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses psoriatic arthritis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for psoriatic arthritis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The psoriatic arthritis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.